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Abstract
Background: Enterovirus 71 (EV71) has emerged as a major causative agent of hand, foot and mouth disease in the
Asia-Pacific region over the last decade. Hand, foot and mouth disease can be caused by different etiological agents
from the enterovirus family, mainly EV71 and coxsackieviruses, which are genetically closely related. Nevertheless,
infection with EV71 may occasionally lead to high fever, neurologic complications and the emergence of a rapidly fatal
syndrome of pulmonary edema associated with brainstem encephalitis. The rapid progression and high mortality of
severe EV71 infection has highlighted the need for EV71-specific diagnostic and therapeutic tools. Monoclonal antibodies
are urgently needed to specifically detect EV71 antigens from patient specimens early in the infection process.
Furthermore, the elucidation of viral epitopes will contribute to the development of targeted therapeutics and vaccines.
Results: We have identified the monoclonal antibody 7C7 from a screen of hybridoma cells derived from mice
immunized with the EV71-B5 strain. The linear epitope of 7C7 was mapped to amino acids 142-146 (EDSHP) of the
VP2 capsid protein and was characterized in detail. Mutational analysis of the epitope showed that the aspartic
acid to asparagine mutation of the EV71 subgenogroup A (BrCr strain) did not interfere with antibody recognition.
In contrast, the serine to threonine mutation at position 144 of VP2, present in recently emerged EV71-C4 China
strains, abolished antigenicity. Mice injected with this virus strain did not produce any antibodies against the VP2
protein. Immunofluorescence and Western blotting confirmed that 7C7 specifically recognized EV71
subgenogroups and did not cross-react to Coxsackieviruses 4, 6, 10, and 16. 7C7 was successfully used as a
detection antibody in an antigen-capture ELISA assay.
Conclusions: Detailed mapping showed that the VP2 protein of Enterovirus 71 contains a single, linear, non-
neutralizing epitope, spanning amino acids 142-146 which are located in the VP2 protein’s E-F loop. The S/T(144)
mutation in this epitope confers a loss of VP2 antigenicity to some newly emerged EV71-C4 strains from China.
The corresponding monoclonal antibody 7C7 was used successfully in an AC-ELISA and did not cross-react to
coxsackieviruses 4, 6, 10, and 16 in immunofluorescence assay and Western blots. 7C7 is the first monoclonal
antibody described, that can differentiate Coxsackievirus 16 from Enterovirus 71.
Keywords: Hand, foot and mouth disease, Enterovirus 71, Coxsackievirus A16, VP2 capsid protein, Linear epitope,
Monoclonal antibody, Antigen capture ELISA
Background
Human enterovirus 71 is a member of the enterovirus A
species within the genus Enterovirus of the family Picorna-
virus. Picornaviridae are small (30 nm), non-enveloped,
single-stranded RNA viruses that are responsible for a
variety of communicable diseases in humans such as
poliomyelitis, hepatitis A, the common cold as well as
hand, foot and mouth disease (HFMD). Enteroviruses are
distinguished from other picornaviruses on the basis of
their physical properties and encompass polioviruses, rhi-
noviruses, echoviruses, coxsackieviruses and the “EV”
enteroviruses. The human enteroviruses are now classified
into 4 species: human enterovirus A (HEV-A) including
coxsackievirus CAV4, 6, 10 and 16 and EV71, HEV-B,
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HEV-C, and HEV-D [1]. Since its first description in 1974
[2], there were periodic outbreaks of EV71 infection
throughout the world. Over the last decade, EV71 has
become endemic in the densely populated Asia-Pacific
region, and epidemic outbreaks of HFMD occur frequently
in Singapore, Taiwan, Malaysia, and China, raising con-
cerns that the virulence and prevalence of EV71 may be
increasing [3]. Furthermore, rapid mutation rates result in
the emergence of new subgenotypes every few years [4].
To date, 11 EV71 subgenogroups have been identified
based on comparison of their VP1 sequence: A, B1-B5,
C1-C5 [5]. The Asian pandemics have been associated
with co-circulation of different genetic lineages and the
emergence of novel strains [6-9].
Although EV71 infection mainly manifests as HFMD
in young children, the potential of enteroviruses to
attack the central nervous system was first witnessed in
a large epidemic in Bulgaria (1975) and Hungary (1978)
where prominent neurologic manifestations such as
aseptic meningitis, brainstem encephalitis and acute
flaccid paralysis were observed [10,11]. HFMD can be
caused by different etiological agents of the enterovirus
family, mainly EV71 and CA16 [12] and molecular stu-
dies have shown a close genetic similarity between these
two viruses [13]. Nevertheless, infection with EV71
more often leads to high fever and neurologic complica-
tions in children under 5 years of age [14-16] and the
case-fatality rate of EV71 infection with complications
ranges from 10% to 26% [17]. Especially worrying was
the emergence of a rapidly fatal syndrome of pulmonary
edema associated with brainstem encephalitis [18]. The
occurrence of more frequent EV71 pandemics associated
with severe neurological disease and fatalities has high-
lighted the need for EV71-specific diagnostic and thera-
peutic tools.
The EV71 virus particle consists of a naked icosahedral
capsid composed of the four structural proteins VP1-4
surrounding a single-stranded positive-strand RNA of
about 7.4 kb. The viral RNA contains a single open read-
ing frame coding for a polyprotein which is autocatalyti-
cally cleaved after translation. P1, P2, and P3 are three
distinct regions on the polyprotein that encode the struc-
tural proteins (P1) and the seven accessory proteins 2A-
C and 3A-D (P2 & P3). The functions of these 11 EV71
proteins are thought to be identical to those described
for poliovirus and other enteroviruses [19]. The polypro-
tein precursor is processed during translation and the
primary cleavage of P1 and P2 is mediated by 2Apro.
Next, 3CDpro is released from P3 by autocatalysis and
proceeds to cleave P1 into the capsid proteins VP0, VP1,
and VP3. These three structural proteins self-assemble
stepwise into empty capsids. Once the genomic RNA is
loaded into the capsid, the provirion matures into an
infectious virion through the cleavage of VP0 into VP2
and VP4. As the VP0 scissile bond is located inside the
provirion, it is inaccessible to viral or cellular proteases.
The cleavage is thought to be mediated by RNA but the
exact process is yet unidentified. However, recent data
confirms the presence of 3CDpro in the virus particle (in
press), making it a novel candidate for this cleavage. The
three major capsid proteins VP1, VP2, and VP3 have the
same topology: They form an eight-stranded anti-parallel
beta-barrel in the form of a wedge which facilitates pack-
ing. Their main structural differences are the connecting
loops and the C-termini on the outside of the capsid.
VP4, however, has an extended conformation and is
found on the inside of the virion. It is myristylated and
confers stability to the capsid [20]. The VP1 capsid pro-
tein harbors the main neutralizing epitopes of EV71
[21-24] and its sequence variability is used to classify
EV71 into subgenogroups [25]. In addition, neutralizing
or antigenic epitopes on the VP0 and VP2 proteins have
been described in other members of the picornavirus
family including poliovirus [26,27], coxsackievirus A9
[28], foot-mouth-disease virus [29], and parechovirus
[30]. Furthermore, VP0 has been proposed as a diagnos-
tic tool to detect anti-human parechovirus 1 antibodies
in patient sera [31,32].
Due to the increasing number and severity of EV71
infections, diagnostic monoclonal antibodies (MAbs) to
directly detect EV71 virions from patient swabs are
urgently needed. To create such MAbs we have screened
hybridoma cells derived from mice immunized with the
EV71-B5 strain and isolated the MAb designed 7C7.
EV71-B5 (NCBI accession # FJ172159.1) has been iso-
lated from a patient in the large 2008 outbreak of HFMD
in Singapore. The epidemic was characterized by high
transmission but relatively mild disease, coinciding with
the transition of the EV71 subgenogroup from B4 to B5
[33]. Mutational analysis, Western blotting and immuno-
fluorescence assay (IFA) were used to characterize the
epitope of 7C7 and its specificity in detail. We success-
fully employed 7C7 to detect different EV71 subgeno-
types and demonstrated the absence of cross-reactions to
CAV16 in both IFA and Western blots. Additionally, we
performed an antigen-capture ELISA (AC-ELISA) using
polyclonal anti EV71 serum as capture antibody and 7C7
as detection antibody.
Results
Monoclonal antibody production against EV71 VP2
protein
Monoclonal antibodies against inactivated virus were
developed. Mice were immunized subcutaneously with
100 μl of concentrated EV71-B5 strain virus in a 1:1
emulsion with Seppic adjuvans. Two boosters were
administered at 14 day intervals, followed by a final
intraperitoneal boost. Splenocytes were then harvested
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and fused with hybridoma cells according to standard
protocols. Monoclonal antibody screening by IFA and
subsequent subcloning resulted in the isolation of the
VP2-specific MAb 7C7. The MAb was isotyped as IgG1
with kappa light chain by Isostrip (Santa Cruz). The
antibody was able to detect EV71 in infected African
green monkey kidney cells (Vero) as observed by IFA.
No labeling was observed in uninfected cells (Figure
1A). Western blotting of EV71 virus particles from the
C4 (Yamagata) strain revealed that the MAb 7C7 was
specific for VP2 at 28 kDa, and also recognized the pre-
cursor protein VP0 at around 35 kDa (Figure 1B). Poly-
clonal guinea pig anti-EV71 serum and monoclonal
anti-VP1 antibody (in house production) were used as
positive controls. To test the sensitivity of MAb 7C7, a
dot blot assay was performed. EV71-B5 virus was dotted
at dilutions of 106.6 to 103.6 TCID50 units per dot, and
labeled with 7C7. Purified influenza virus H7N1 served
as a negative control. The detection limit was around
105 TCID50 units (Figure 1C). No neutralization activity
was observed in a virus neutralization assay.
Epitope mapping of 7C7 anti-VP2 MAb
To characterize the 7C7 epitope, the VP2 protein was
fragmented into GST-tagged continual overlapping pep-
tides, cloned into pGex-4 T-1 vector and expressed in E.
coli BL21 cells. Expression of the fusion proteins was
monitored by Western blotting with anti-GST. By gra-
dual reduction of the fragment length, the epitope loca-
tion was narrowed down from amino acids 130 to 162
(Figure 2A) to fragment “d” between amino acids 145-
159 (Figure 2B) and finally to peptide “4” corresponding
to amino acids EDSHPP (Figure 2C). This sequence was
subjected to BLAST analysis against complete EV71
sequences in the NCBI database, and two single amino
acid variations were identified. An aspartic acid to
asparagine substitution (ENSHPP) was present in the
EV71-A (BrCr strain) subgenogroup and CAV16 while a
threonine instead of serine (EDTHPP) was present in
some EV71-C4 China strains. Furthermore, the human
echovirus epitope contained a double substitution of
serine to asparagine and histidine to alanin (EDNAPP)
at positions two and three, respectively (Table 1). We
expressed these putative epitopes EDSHPP, EDSHP,
ENSHPP, EDTHPP, EDTHP, and EDNAPP as GST-
fusion proteins, and assessed recognition by MAb 7C7.
Expression of GST fusion peptides showed that the
minimal epitope of 7C7 were the five amino acids
EDSHP which correspond to positions 142-146 of the
EV71 VP2 capsid protein (Figure 2D, lane 4). 7C7 was
also able to detect the EV71-A (BrCr) and CAV16 epi-
tope variant ENSHPP (Figure 2D, lane 5). There was no
recognition of the echovirus double mutant EDNAPP,
confirming the exclusive specificity of 7C7 to EV71 and
maybe CA16 (Figure 2D, lane 8). To our surprise, the
EDTHP epitope variant, present in some EV71-C4
China strains, was not recognized by 7C7 (Figure 2D,
lane 7). By constructing a phylogenetic tree of published
EV71 sequences, we could demonstrate that the 30
EV71 sequences containing the serine to threonine sub-
stitution all belong to the C4 subgenogroup isolated in
recent years (2008 - 2010) in China (Table 2). This
includes the C4-Fuyang-08 strain which was engineered
in our lab by reverse genetics [34].
Specificity of 7C7 to EV71 subgenogroups
To corroborate the findings of the mutational analysis
conducted above, we infected RD cells with EV71 viruses
from different subgenogroups and performed a Western
blot. The selected wild-type strains were A (BrCr), B2
(7423-MS-87), B4 (HFM41), B5 (NUH0083-SIN-08), C1
(Y90-3761), C4 (75-Yamagata-03), and C5 (3437-SIN-
06). In addition, cells were infected with reverse geneti-
cally engineered (RG) virus of the C4-Fuyang-08 strain
carrying the serine to threonine mutation in the 7C7 epi-
tope. Cytopathic effect could be observed in more than
Figure 1 Characterization of MAb 7C7. IFA (A), Western blot (B),
Dot blot (C) of EV71 virus with MAb 7C7. (A) IFA of EV71 infected
Vero cells. Cells were labeled with MAb 7C7 followed by anti-mouse
FITC secondary antibody. Top panel: Vero cells infected with EV71-
B5 (NUH0083). Bottom panel: Non-infected Vero cells. (B) Western
blot of sucrose purified EV71-C4 strain (75-Yamagata-03). Blots were
labeled with primary antibodies and HRP coupled secondary
antibodies and bands were developed by ECL. Lane 1: Polyclonal
guinea pig anti-EV71 (B5 strain) antibody detects all three capsid
proteins VP0/2 (arrows), VP1 and VP3 (arrowheads). Lane 2:
Monoclonal anti-VP1 antibody (in press) specifically labels the VP1
band (arrowhead). Lane 3: MAb 7C7 recognizes VP2 at about 28
kDa and its precursor VP0 at around 35 kDa (arrows). (C) Sensitivity
of MAb 7C7 in a dot blot assay. EV71-B5 virus was dotted at 10-fold
dilutions of TCID50 units per dot, labeled by MAb 7C7 and detected
by HRP-coupled secondary antibody. H7N1 virus served as negative
control. The detection limit was around 10^5 TCID50 units.
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90% of the cells at 48 h post-infection when the superna-
tants were collected. Cell debris was removed by a clarifi-
cation spin and microfiltration through a 0.2 um cut-off
filter and virus was then inactivated with BEI. Inactivated
virus was concentrated by ultraspin, and subjected to
SDS-PAGE. Western blotting using 7C7 as primary anti-
body and HRP-labeled secondary antibody was per-
formed and the signal was detected by ECL. In all the
strains carrying the ED/NSHP epitope, two specific
bands corresponding to VP0 and VP2 could be detected
(Figure 3, arrows), while there was no signal for the C4
strain RG virus. IFA gave the same results (Additional
file 1).
Serine to threonine mutation at position 144 of VP2
abolishes antigenicity
In order to investigate the role of the serine to threo-
nine mutation in some recent EV71-C4 China strains,
Figure 2 Epitope Mapping of MAb 7C7. (A) Fragmentation of the VP2 protein into 7 continual overlapping segments. Western blotting of the
fragments with anti-GST showed expression of all constructs, while blotting with 7C7 did not recognize fragments F and G, indicating that the
epitope lies between amino acids 130 and 162 of VP2. (B) Fragmentation of amino acids 1-159 of VP2 into 6 continual overlapping segments.
Again, blotting with anti-GST confirms protein expression, while blotting with 7C7 indicates that the epitope lies on fragment “d” between
amino acids 145-159 of VP2. (C) Fragmentation of “d” into 6 continual overlapping peptides. Anti-GST blotting shows expression while the
epitope of 7C7 is restricted to peptide “4” corresponding to amino acids EDSHPP. (D) Mutational analysis of the putative 7C7 epitope EDSHPP:
Mutated epitopes were expressed as GST fusion proteins and expression was confirmed by Western blotting with anti-GST antibody. The
minimal epitope EDSHP as well as the aspartic acid to asparagine substitution (ENSHPP) present in EV71 BrCr strain and CAV16 could be
recognized by our MAb 7C7. However, the threonine to serine mutation (EDTHPP) of some C4 strains and the double mutation of human
echoviruses (EDNAPP) could not be recognized.
Table 1 Alignment of VP2 amino acid (131-155) sequences of EV71 subgenogroups and CAV16
Genogroup Strain GenBank # Sequence
C4 Fuyang-08 EU703813.1 VIGTVAGGTGTEDTHPPYKQTQPGA
C4 75-Yamagata AB550338.1 VIGTVAGGTGTEDSHPPYKQTQPGA
C2 NUH0075/SIN/08 FJ172159.1 VIGTVAGGTGTEDSHPPYKQTQPGA
B2 7423-MS-87 U22522.1 VIGTVAGGTGTEDSHPPYKQTQPG
B4 5865/SIN/09 AF316321.2 VIGTVAGGTGTEDSHPPYKQTQPGA
B5 NUH0083/SIN/08 FJ461781.1 VIGTVAGGTGTEDSHPPYKQTQPGA
A BrCr U22521.1 VIGTVAGGTGTENSHPPYKQTQPGA
CAV16 CAV16 U05876 VLGTIAGGDGNENSHPPYVTTQPGQ
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we compared polyclonal antisera of mice immunized
with either EV71-B5 (used to isolate MAb 7C7) or RG
virus EV71-C4-Fuyang, carrying the mutation. The anti-
sera were assayed for their ability to detect VP2 protein
in Western blots. As targets, we loaded recombinant full
length VP2 protein with His tag cloned from EV71-C4-
Fuyang strain, recombinant full length VP2-GST fusion
protein cloned from EV71-B5 strain, wild-type virus
EV71-C4-Yamagata which carries the consensus epitope
EDSHP and RG virus EV71-C4-Fuyang with the EDTHP
mutation. The polyclonal serum from EV71-B5 injected
mice could recognize VP1 in both C4 strains (Figure 4A,
arrowhead). It was also able to detect VP0 and VP2 in
the C4-Yamagata strain (Figure 4A, arrows) and detected
the recombinant VP2-B5 protein (Figure 4A, box 3).
Anti-EV71-B5 serum however could not detect VP0 or
VP2 in the in C4-Fuyang RG virus nor could it detect the
full length VP2-Fuyang protein (Figure 4A, lanes 2 & 3).
Next, we tested polyclonal serum from mice injected
with C4-Fuyang RG virus. Again, VP1 was detected in
both C4-Yamagata and C4-Fuyang (Figure 4B, arrow-
heads) and there was recognition of a putative VP0 band
(Figure 4B, arrows). However, the C4-Fuyang serum con-
tained no antibodies against VP2 (Figure 4B, boxes). The
expression level of VP2-C4-Fuyang protein was moni-
tored by anti-his antibody (Figure 4C). Taken together,
these results show that there is only a single linear VP2
epitope on the EV71 virus and that the mutation of ser-
ine (144) to threonine (144) in this epitope confers a loss
of VP2 antigenicity to some newly emerged C4-China
strains.
7C7 is specific for EV71 and does not recognize
coxsackieviruses
So far, no MAbs have been identified, that are specific
exclusively for EV71 subgenogroups [35]. We therefore
tested our new MAb 7C7 for cross reactivity to several
strains of coxsackieviruses, namely CAV4, 6, 10 and 16 in
both IFA (Additional file 2) and Western blot. The entero-
virus A specific MAb 4B12, which reacts with the 3D poly-
merase and 3CD proteinase (in press), was used as a
control to monitor the replication of the CAV. RD cells
were infected with either EV71, CAV4, 6, 10 or 16. CPE
was apparent 48 h post infection when cell supernatants
were collected and concentrated as described above. MAb
7C7 did not cross-react to CAV4, 6, 10 and 16 in Western
blotting of concentrated virus particles (Figure 5). At first
glance this result conflicted with our epitope analysis, but
comparison of the six amino acids surrounding the mini-
mal epitope, showed four substitutions in CAV16 versus
EV71-A. The flanking region in all EV71 strains including
BrCr is TGT-epitope-YKQ whereas the flanking region of
our CAV16 strain is DGN-epitope-YVT. CAV16 has a
threonine to aspartic acid (nucleophilic to acidic) and a
threonine to asparagine (nucleophilic to amide) substitu-
tion on the 5’ end of the minimal epitope and a lysine to
alanine or valine plus a glutamine to threonine substitu-
tion (positive charge to hydrophobic, amide to nucleophi-
lic respectively) at the 3’end (Table 1). These alterations
might prevent the binding of MAb 7C7 to the minimal
epitope due to sterical hindrance in the context of the
whole CAV16 virus.
Antigen-capture ELISA
The MAb 7C7 was tested as a detection antibody in an
AC-ELISA assay. First, we performed a checkerboard
titration was performed. A signal to noise ratio of 3 was
obtained for 100 ng-1ug capture serum and 1 ug of
detection Ab. To evaluate the sensitivity of the AC
ELISA, 500 ng of rabbit polyclonal anti-EV71 antibody
(in house production) was coated in each well of the
ELISA plate. Clarified supernatant from EV71-B5 infe-
ceted RD cells was then added at dilutions of 107, 106,
Figure 3 Specificity of 7C7 to EV71 subgenogroups. Western
blot of concentrated virus particles from EV71 strains A (BrCr), B2
(7423-MS-87), B4 (HFM41), B5 (NUH0083-SIN-08), C1 (Y90-3761), C4
(75-Yamagata-03), C5 (3437-SIN-06), and C4-Fuyang RG virus. RD
cells were infected with EV71 and the supernatants were collected
and clarified. Blots were incubated with 7C7 followed by HRP-
coupled secondary antibody. Bands for VP0 (35 kDa) and VP2 (28
kDa) could be detected in all strains except the RG virus carrying
the serine to threonine mutation in the 7C7 epitope.
Table 2 EV71-C4 strains with S/T(144) mutation
Year GenBank # Year GenBank # Year GenBank #
2010 ADX87405.1 2010 ADX36154.1 2010 ADR73044.1
2010 ADG57604.1 2010 ADJ37050.1 2010 ADJ37049.1
2010 ADI49646.1 2010 ADI49645.1 2010 ADI49642.1
2010 ADC84177.1 2010 ADC84176. 2010 ADC54995.1
2010 ACY00665.1 2010 ACY00664.1 2009 ACX46121.1
2009 ACU45381.1 2009 ACU45378.1 2009 ACU45377.1
2009 ACM62758.1 2009 ACM62757.1 2009 ACJ70062.1
2008 ACJ04794.1 2008 ACJ04792.1 2008 ACI25379.1
2008 ACI03062.1 2008 ACI03061.1 2008 ACF60581.1
2008 ACF21980.1 2008 ACD63040.1 2008 ACD63039.1
2008 ACD63041.1
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Figure 4 Antigenicity of VP2 is abolished in S/T(144) mutant EV71 strains. Polyclonal sera from mice injected with either wild-type EV71-B5
or EV71-C4-Fuyang RG virus were tested for the presence of anti-VP2 antibodies. Western blots were performed on samples of EV71-C4-
Yamagata virus, EV71-C4-Fuyang virus, recombinant VP2-C4-Fuyang protein carrying a His tag, and recombinant VP2-B5-GST fusion protein
protein. (A) Serum from EV71-B5 injected mice was used as a control. This serum could recognize VP1 in both C4 strains (arrowhead). It was also
able to detect VP0 and VP2 in the EV71-C4-Yamagata stain carrying the consensus epitope EDSHP (arrows). There was no recognition of VP0 and
VP2 in EV71-C4-Fuyang or of full length VP2-C4-Fuyang protein containing the S/T(144) mutation. In contrast, recombinant VP2-GST fusion
protein from B5 strain was detected. (B) Serum from mice injected with EV71-C4-Fuyang was tested for the presence of anti-VP2 antibodies.
Again, VP1 protein could be detected in both C4 strains (arrowheads). Additionally, there might be recognition of VP0 (arrows) but the serum
contained no Abs against VP2 of either C4 virus strain, recombinant VP2-C4-Fuyang protein, or VP2-B5 protein (boxes). (C) Expression control for
VP2-C4-Fuyang protein using anti-His antibody.
Figure 5 7C7 does not detect coxsackieviruses. RD cells were infected with either EV71-B5 strain, CAV16, CAV10, CAV6, or CAV4. Cells were
incubated 48 h until CPE was observed. Supernatants were clarified and concentrated before blotting. As a control for CAV infection, blots were
labeled with enterovirus A specific MAb 4B12 which detected its targets 3D (~52 kD, arrowhead) and 3CD (~73 kD, arrowhead) in all four tested
coxsackievirus strains CAV16, 10, 6 and 4 as well as EV71. However, neither VP0 nor VP2 protein was detected by MAb 7C7 in these samples
(arrows).
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and 105 TCID50 units per well, and detected by MAb
7C7 followed by HRP-labeled anti-mouse antibody.
DMEM media was used as negative control. Color was
developed using freshly prepared substrate solution
(o-phenylenediamine) and OD measured at 490 nm.
The MAb 7C7, targeting the viral capsid protein VP2,
was able to detect 105 TCID50 units of EV71 virus
which corresponds to the amount detected by dot blot-
ting. Again, the signal to noise ratio cut-off was set at 3
times (Figure 6).
Discussion
A syndrome of rapid onset pulmonary edema and brain-
stem encephalitis has been observed in recent large out-
breaks of HFMD in East Asia [15,18]. As these
neurologic complications of HFMD are mainly caused
by infection with EV71 [14,36], there is an urgent need
to develop assays to diagnose EV71 early in infection
and to distinguish HFMD caused by EV71 from the
milder form caused by CAV16. A real time PCR based
molecular test to detect virus from patients has been
developed [37]. However, PCR tests are extremely sensi-
tive and need extensive controls while antigen detection
by MAbs has the advantage of the relative ease of sam-
ple handling and the use of less stringent procedures.
Specific MAbs can then be used to develop a rapid test
such as dip stick or lateral flow. In this study, we have
characterized the epitope of the EV71-specific monoclo-
nal antibody 7C7 in detail. The linear epitope of 7C7
was mapped to amino acids 142-146 within the VP2
capsid protein and further characterized by mutational
analysis. In Western blots, 7C7 could detect bands for
both VP2 and its precursor VP0. MAb 7C7 was also
able to detect all EV71 subgenogroups by IFA and Wes-
tern blot, with the exception of some recent C4 China
strains that carry the S/T(144) mutation in VP2. The
MAb did not cross-react to coxsackieviruses CAV16, 10,
6, and 4 and was used successfully as a capture antibody
in an AC-ELISA.
VP2 is an immunogen of EV71 and its epitope is located
in the E-F loop
The major antigenic determinants of picornaviruses are
usually found on the VP1 capsid protein. This poses the
problem of generating universal antibodies against all
subgenogroups of a virus strain, as the VP1 sequence
also carries most of the mutations defining virus classifi-
cation. VP0 and VP2 have been described to carry anti-
genic determinants in other picornaviruses and might be
more useful for diagnostic purposes due to their higher
sequence conservation between subgenogroups. VP0/
VP2 and VP3 have been shown to form antigenic struc-
tures in a variety of picornavirus family members such as
poliovirus 1, poliovirus 3, coxsackievirus A9 (CVA9),
human rhinovirus 14, and foot-and-mouth disease
(FMDV) virus [26,38-40]. These include conformational
neutralizing epitopes spanning more than one capsid
protein such as N-AgII and N-AgIV of the Sabin polio
virus [27] or the D epitope of FMDV [41], neutralizing
epitopes of VP2 in CVA9 [28], as well as linear epitopes
of VP2 in human parechoviruses [30]. The latter has
been used to create a serological assay to detect parecho-
virus antibodies in human sera [32] confirming the feasi-
bility of exploiting VP2 antigenicity for virus detection.
In our study, we injected mice with inactivated EV71-B5
virus and isolated a MAb that recognized two protein
bands of around 35 kDa and 28 kDa in a Western blot,
corresponding to VP0 and VP2. This demonstrates the
immunogenicity of the EV71 VP2 protein in the context
of the virion. Sequential deletions of the VP2 capsid pro-
tein were used to exactly map the epitope of MAb 7C7 to
amino acids 142 to 146 of VP2. This epitope lies in the
E-F loop protruding out of the b-sheets encompassing
amino acids 130 to 170, as has been described for the VP2
epitopes of other picornaviruses [26,28,38,42]. In addition,
a recent paper described the epitope of the commercially
available anti-VP2 MAb979 (Chemicon, USA) roughly as
amino acids 136-150 which encompasses the exact epitope
EDSHP that we identified. This approximated epitope has
Figure 6 Antigen capture ELISA. 500 ng of rabbit polyclonal anti-
EV71 antibody was coated in each well of the ELISA plate. EV71-B5
virus antigen was added at dilutions of 10^7, 10^6, and 10^5
TCID50 units per well and detected by 1 ug of MAb 7C7 followed
by HRP labeled anti-mouse antibody. DMEM media instead of 7C7
was used as a negative control. O-phenylenediamine as a substrate
was used for color development and the OD was measured at 490
nm. The anti-VP2 MAb 7C7 could detect as little as 10^5 TCID50
units of EV71 captured by polyclonal serum in this ELISA assay.
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been found to be non-neutralizing when injected into
mice, corresponding to our findings [43].
Serine to threonine mutation at position 144 of VP2
abolishes antigenicity of the EV71 VP2 protein
Blast analysis of the exact VP2 epitope revealed two sin-
gle amino acid variations within the EV71 family: D/N
(143) was found in the EV71-A isolate BrCr while the
S/T(144) substitution was limited to some EV71-C4
China strains. Mutational analysis of the epitope showed
that the D/N (143) mutation of the EV71 subgenogroup
A did not interfere with antibody recognition, while the
S/T(144) mutation abolished antibody binding. By ana-
lyzing polyclonal serum from mice immunized with
EV71-C4 RG virus carrying the S/T(144) mutation, we
proved that no antibodies were formed against VP2 in
these mice. Our results clearly show that there is only a
single linear VP2 epitope on the EV71 virus and that the
mutation of S/T(144) confers a loss of VP2 antigenicity
to recently emerged EV71-C4 strains from China. A total
of 30 published sequences were found to carry this muta-
tion, while the majority of C4 strains from China and
other countries had the conserved epitope and could be
recognized in our assays.
MAb 7C7 does not cross-react with CAV16 and can be
used in an AC-ELISA
Many mABs generated against enteroviruses turned out
to cross-react to one or more different species and so far,
no mABs have been described that can distinguish EV71
from CAV16 virus. In the only EV71 study where cross-
reactivity was tested, the MAb raised against the EV71
VP1 protein did indeed cross-react [44]. A blast of the
7C7 epitope on the NCBI database revealed its high spe-
cificity: Besides EV71, only CAV16 and the human echo-
virus 30 sequences carried related epitopes. Mutational
analysis of the 7C7 minimal epitope showed recognition
of the major EV71 epitope EDSHP as well as ENSHPP of
EV71-A (BrCr) and CAV16. IFA and Western blotting of
wild-type virus strains, however, showed that 7C7 exclu-
sively recognized EV71 and did not cross-react to
CAV16. Sequence analysis of the amino acids immedi-
ately surrounding the minimal epitope ENSHPP of
CAV16 revealed four substitutions, including a nucleo-
philic to acidic and a positive charge to hydrophobic
change, which might cause sterical hindrance to the
binding of the MAb to the whole CAV16 virus. To test
the suitability of MAb 7C7 in antigen detection, we per-
formed an AC-ELISA using polyclonal anti-EV71 serum
from rabbit as a capture Ab for EV71 virus particles and
7C7 as a detection Ab. We successfully detected a mini-
mum of 105 TCID50 units of EV71 virus corresponding
to the detection limit in the dot blot assay. Even tough
7C7 is not the perfect candidate for universal diagnosis, it
nevertheless is the only MAb described so far that can
differentiate between CAV16 and EV71.
Conclusions
Detailed mapping of the epitope of MAb 7C7 allowed us
to conduct mutational analysis with regard to EV71 and
CAV lineages. We were able to demonstrate that there
is only a single linear epitope on the VP2 protein of
EV71, namely ED/NSHP comprising amino acids 142-
146. The S/T(144) mutation in this epitope confers a
loss of antigenicity to the VP2 protein of some newly
emerged EV71-C4 strains from China. The MAb 7C7
was shown to exclusively recognized EV71 as it did not
cross-react to coxsackieviruses 4, 6, 10, and 16 in IFA
and Western blots. 7C7 is thus the first MAb that can
differentiate CAV16 from EV71 and it was used success-
fully in an AC-ELISA.
Materials and methods
Viruses and cells
Wild-type enterovirus 71 and coxsackievirus strains were
received from the Human Genome Laboratory, Depart-
ment of Microbiology, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore. Additionally,
the RG virus EV71-C4-Fuyang (NCBI accession
#EU703813.1) has been constructed in the lab by reverse
genetics. All virus strains have been propagated in rhabdo-
myosarcoma (RD) cells grown in DMEM medium (Gibco)
with 10% fetal bovine serum (FBS). Virus was added to the
culture medium, incubated at 37°C for 48 h when over
90% of cytopathic effect (CPE) was observed. The superna-
tant was collected and the virus activity was tested on RD
cells in an end-point dilution assay (Reed & Muench,
1938) to calculate the tissue culture infective dose
(TCID50). Before further experimentation, virus was inacti-
vated with BEI. A 0.2 M solution of 2-bromoethylamine
hydrobromide in 0.4 M NaOH (BEI) was prepared and
incubated overnight at room temperature. BEI (3.2 mM)
was then added to the cell supernatant containing virus
and incubated for 48 h at 37°C. BEI was neutralized with
1/10 total volume of 1 M sodium thiosulfate. Cell superna-
tant was then clarified by centrifugation at 7,500 g for
30 min and filtration through a 0.2 um cut-off filter (Milli-
pore). The virus was concentrated 20 times by an ultraspin
at 100,000 g for 3 h and resuspended in PBS.
Preparation and purification of MAb 7C7 from whole
EV71 virus
All animal experiments were carried out in accordance
with the Guides for Animal Experiments of the National
Institute of Infectious Diseases (NIID), and experimental
protocols were approved by the Institutional Animal
Care and Use Committee of the Temasek Life Sciences
Laboratory. Hybridomas secreting specific MAbs were
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derived from BALB/c mice which had been immunized
twice subcutaneously with inactivated and concentrated
EV71-B5 strain in 0.1 ml of PBS, emulsified with an
equal volume of adjuvant (SEPPIC, France). An intraper-
itoneal booster of the same dose of virus was adminis-
tered 3 days before splenocytes were fused to the SP2/0
myloma cells, as previously described [45]. Hybridomas
were screened by IFA of Vero cells infected with EV71-
B5. Clones identified to produce specific antibody were
then sub-cloned by limiting dilution, and expanded in
75 cm2 flasks. One week later, the hybridoma suspen-
sion was harvested and cell debris pelleted by centrifu-
gation at 400 g for 10 min, followed by collection of the
supernatant and storage at -20°C. Ascites fluid was pro-
duced by intraperintoneal injection of hybridoma cells
in balb/c mice followed by MAb purification with the
Montage Prosep-A antibody purification kit (Millipore,
USA). MAb was isotyped using Isostrip (Santa Cruz,
USA) and concentrations were determined spectro-
photometrically (Nanodrop, DE).
Immunofluoresence Assay (IFA)
For antibody screening, Vero African green monkey kid-
ney cells were seeded overnight onto 96-well plates in
DMEM with 10% FBS at approximately 90% confluence
and infected with 100 μl virus at 105 TCID50. Vero cells
were incubated at 37°C for 48 h when CPE could be
observed, and for 15 min in 4% paraformaldehyde/PBS
(pH 7.4) and permeabilized with 0.1% Triton-X/PBS for
15 min. After blocking with 10% fetal bovine serum/PBS
for 1 h, cells were incubated in hybridoma cell superna-
tant for 1 h followed by three 15 min washes in 0.1%
Tween/PBS. FITC-coupled secondary antibody was
applied for 1 h, again followed by three 15 min washes
in 10% Tween/PBS. All steps were performed at room
temperature. Results were documented in an inverted
microscope (Olympus) with Nikon ACT-1 software.
Western Blotting
Protein samples were obtained from concentrating EV71
virus particles by ultraspin and from E. coli cell lysis and
sonication (GST-fusion proteins, His-tagged proteins).
Protein samples were denatured in loading buffer (Tris
pH 6.8, Glycerol, 20% SDS) with 5% b-mercaptoethanol,
and heated at 95°C for 5 min. 10-12% SDS-PAGE gels
were prepared according to standard protocols, and elec-
trophoresed at 100 volts for 3 h. Proteins were then
transferred to nitrocellulose membranes (TransBlot,
BioRad) by wet western blotting at 100 volts for 2 h in
transfer buffer (12.5 mM Tris, 96 mM Glycine, 10%
Methanol). Blots were blocked in 5% blotting grade milk/
PBS and incubated in a 1:100 dilution of polyclonal anti-
EV71 serum (Figure 1B), or hybridoma cell supernatant
for 1 h each. Membranes were washed three times for
15 min each in 0.1% Tween-20/PBS before incubation in
horse-radish-peroxidase coupled secondary antibody
diluted 1:10,000 (Dako Cytomation) for 1 h. Membranes
were washed again three times for 15 min each in 0.1%
Tween-20/PBS followed by incubation with chemolumi-
nescent ECL reagent (Amersham) and detection with
Hyperfilms (Amersham). All steps were performed at
room temperature.
Dot Blotting
Wild-type virus strain C4-Yamagata propagated in RD
cell supernatants was serially diluted to a TCID50 ran-
ging from 106.6 to 103.6. 50 ulof virus dilution was
mixed with 200 ulof transfer buffer (20 mM Tris pH
7.5, 500 mM NaCl), and applied to a dot blot apparatus
(BioRad) containing a nitrocellulose membrane (Trans-
Blot, BioRad). A vaccum pump was used to adsorb the
sample to the membrane, and an additional 100 ulof
transfer buffer was added as a wash. The blot was then
processed as a Western blot as described earlier. Signals
were developed by ECL (Amersham). All steps were per-
formed at room temperature.
Construction of GST fusion proteins with fragments of
VP2 sequence for epitope mapping
Total RNA was extracted from EV71-B5 with RNAeasy
kit (Qiagen, Germany) according to manufacturer’s pro-
tocol. Full length VP2 gene was then amplified by
reverse transcription PCR and cloned into pGEX-4 T-1.
Fragments of 3’ end-truncated VP2 gene were then
amplified with the respective primers using full length
pGEX-4 T-1-VP2 as template. Additionally, alternative
epitopes were expressed by incorporating the specific
DNA sequence in the sense primer and using pGEX-4
T-1 as the template. PCR products were double-digested
with EcoRI and XhoI and ligated into pGEX-4 T-1.
Recombinant vectors were sequenced and transformed
into E. coli BL-21 cells for the expression of glutathione
S-transferase (GST) fusion proteins. The positive trans-
formants were grown in Luria-Bertani (LB) medium
with 100 μg/ml of amplicillin at 37°C on a shaker until
an OD600 of 0.6- 0.8 was reached. Cells were then
induced for 3 h by 1 mM isopropyl-b-D-thiogalactopyra-
noside (IPTG) at 37°C and sonicated for 5 min. These
GST fusion proteins were detected with anti-GST MAb
by Western blot hybridization. Alternatively, the VP2-
C4-Fuyang protein was amplified from a synthetic gene
(GenScript, Nanjing, China) designed according to the
published sequence of the EV71-C4 Fuyang-08 subge-
nogroup (NCBI accession # EU703813.1). It was cloned
into the pet-28a vector (Novagen, USA) with an
N-terminal His-tag. After transformation and sequen-
cing of positive clones, the protein was expressed in
E. coli BL-21 cells as described above.
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Antigen capture ELISA
96-well, round-bottom microtiter plates (Nunc, Ros-
kilde, Denmark) were coated with 500 ng per well of
polyclonal rabbit anti-EV71-B5 capture antibody
(raised in house) in 100 ul of carbonate buffer (73 mM
sodium bicarbonate and 30 mM sodium carbonate, pH
9.7) overnight at 4°C. After each incubation with anti-
body or antigen, the plates were washed twice with
PBST, followed by two washes with PBS. The anti-
body-coated plates were blocked with 100 ul of block-
ing buffer (PBS containing 5% milk) for 1 h at room
temperature, and then incubated at 37°C for 1 h with
100 ul of virus-containing clarified supernatant diluted
in PBST. Virus binding was detected by incubation
with 1 ug of purified monoclonal detection antibody
for 1 h at 37°C. 100 ul of 1:3000 HRP conjugated anti-
mouse antibody (Dako, Denmark) was used for label-
ing for 1 h at 37°C, and 100 ul freshly prepared sub-
strate solution (o-phenylenediamine-dihydrochloride;
Sigma, USA) was added as chromogen. The reaction
was stopped by 0.1 M sulfuric acid, and the optical
density at 490 nm respectively was measured with an
ELISA reader (Tecan, Switzerland). The detection limit
was determined as the optical density value that
yielded a signal-to-noise ratio of 3.
Additional material
Additional file 1: Specificity of 7C7 to EV71 subgenogroups by IFA.
To corroborate the findings of the Western blot, we infected African
green monkey kidney cells (Vero) with EV71 viruses from different
subgenogroups and performed IFA. The selected wild-type strains were
A (BrCr), B2 (7423-MS-87), B4 (HFM41), B5 (Malaysia, unpublished
sequence), B5 (NUH0083-SIN-08), C1 (Y90-3761), C2 (NUH0075-SIN-08), C4
(75-Yamagata-03), and C5 (3437-SIN-06) previously grown in
rhabdomysarcoma (RD) cells. Furthermore, Vero cells were infected with
reverse genetically engineered (RG) virus of the C4-Fuyang-08 strain
carrying the serine to threonine mutation in the 7C7 epitope. Cytopathic
effect could be observed at 48 h post-infection when cells were fixed
and labeled with 7C7 followed by anti-mouse FITC labeled secondary
antibody. All tested wild-type strains were positively identified by our
MAb whereas the RG virus could not be detected.
Additional file 2: 7C7 does not recognize coxsackieviruses by IFA.
IFA with MAbs 7C7 (A) and 4B12 (B). Vero cells were infected with either
EV71-B5 strain, CAV16, CAV10, CAV6, or CAV4. Cells were incubated 24 h
until CPE was observed (see bright field images) at which time point the
cells were fixed and processed for IFA. (A) IFA was conducted with MAb
7C7 and FITC labeled secondary antibody. No labeling was observed in
the CAV infected cells. (B) As a control for CAV infection, cells were
labeled with enterovirus A specific MAb 4B12 (in house production),
followed by anti-mouse FITC secondary antibody. All CAV strains were
detected, confirming virus replication.
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